R & D Committee member companies' R&D needs
This section summarizes the needs of R & D Committee member companies for academia and start-ups.
- Please click on the company name to access their innovation-related websites.
- Some companies include a message to academia and startups and contact information under the company name.
- Please review the information on each company and contact them directly with your request.
A-row
Asahi Kasei Therapeutics Corporation
(Updated on April 1, 2026)
Asahi Kasei Therapeutics is promoting open innovation activities to further strengthen introductions and alliances from Japan and abroad.
Through collaborative innovation, Asahi Kasei Therapeutics aims to create breakthrough new drugs for diseases with high unmet medical needs and "reduce to zero the number of people who give up what they want to do because of their disease. Our goal is to "reduce to zero the number of people who give up what they want to do because of their disease.
For more information, please visit our open innovation website.
Astellas Pharma Inc.
(Updated October 28, 2024)
Astellas aims to expand its pipeline through partnering in order to deliver "value" to patients who are waiting for a cure. Our partnering team explores opportunities with partners that align with Astellas' strategy under the philosophy of open innovation.
AstraZeneca K.K.
AstraZeneca is interested in partnering with companies, universities and research institutions in the following areas and fields of drug discovery and R&D
Target Areas and Fields
- Oncology (cancer)
- Cardiovascular, Renal and Metabolic Diseases
- Respiratory/Immunological Diseases
- Vaccine/Immunotherapy
Inquiry
AstraZeneca Corporation Research & Development DivisionBiotech.Transfer.Japan@astrazeneca.com
Alfresa Pharma Corporation
(Listed on December 1, 2025)
Focused disease areas
- Sleep Disorders
- Neurological Diseases
- Pediatric Special Fields
- Areas of High Unmet Medical Needs
- Emergency and critical care
- Gastrointestinal Diseases
- Autoimmune Diseases
Inquiry
www.alfresa-pharma.co.jp/support/form/EA Pharma Co., Ltd.
We are looking for drug discovery research partners who are interested in collaborations and joint research on drug discovery, development, and basic drug discovery technology research related to gastrointestinal diseases. Although our disease area is gastrointestinal diseases, we would like to integrate research in various fields other than gastrointestinal diseases to develop therapeutic drugs from new perspectives and ideas. To this end, we will consider proposals for collaboration and applications in other disease areas as well as in pharmacy, engineering, and science and technology.
Eisai Co., Ltd.
(Updated July 29, 2024)
Our goal is to develop therapeutics for Alzheimer's disease and a wide range of dementias following amyloid beta and tau, and we are seeking proposals from scientists with unique ideas and research programs in these areas. For more information, please visit our corporate website above.
OTSUKA PHARMACEUTICAL Co., Ltd.
Focused disease areas
- Neuropsychiatric Diseases
- Neurodegenerative Diseases
- Kidney/Circulatory Diseases
- Autoimmune Diseases
- Immune System/Inflammatory Diseases
- Blood cancer
- Ophthalmologic Diseases
- Rare Diseases
Inquiry
OPC_Partnering@otsuka.jpONO PHARMACEUTICAL CO., LTD.
(Updated October 28, 2024)
We have designated oncology, immunology, neurology, and specialty areas with high medical needs as our focus areas.
By actively promoting open innovation, we aim to create breakthrough drugs that have a significant medical impact by utilizing advanced technologies and selecting the most appropriate modality (therapeutic means) for our original drug discovery seeds.
Inquiry
customer_info@ono-pharma.comK-row
KISSEI PHARMACEUTICAL CO., LTD.
Kissei's priority therapeutic areas are urology, renal and dialysis, and intractable and rare diseases. Kissei focuses its management resources on these areas to create unique and competitive drugs. In in-house drug discovery, we focus on small molecule drug discovery, aiming to create new drugs that can achieve unprecedented innovation and usefulness for targets that can take advantage of small molecule strengths. Hisamitsu Pharmaceutical is committed to the development of new drugs through transdermal drug discovery and evaluation.
KYORIN Pharmaceutical Co.,Ltd.
(Published on October 28, 2024)
Kyowa Kirin Co., Ltd.
Kowa Company, Ltd.
(Updated July 29, 2024)
Kowa Company, Ltd. focuses its research and development in the following areas
Lifestyle-related diseases
- Dyslipidemia
- Type 2 Diabetes Mellitus
- Arteriosclerotic Diseases
Immunology and inflammation area
- Autoimmune Diseases
- Inflammatory Diseases
- Skin Diseases
Sensory system area
- Eye disease
- Hearing and Balance Function System Diseases
S-row
Sanofi K.K.
SANWA KAGAKU KENKYUSHO CO., LTD.
(Published on October 28, 2024)
We promote open innovation drug discovery of small molecule and nucleic acid drugs without being specific to a disease area.
SHIONOGI & CO., LTD.
(Updated on February 17, 2026)
SHIONOGI is committed to the total care of infectious diseases and the realization of a vibrant and affluent lifestyle. In order to effectively identify various partnering opportunities, we have published a Wish List of research themes that we are interested in on our website.
Sumitomo Pharma CO., LTD.
T-row
DAIICHI SANKYO CO., LTD.
Daiichi Sankyo is taking a number of open innovation initiatives aimed at expanding its external drug discovery network and securing diverse sources of innovation. We are always looking for new drug target molecules, useful evaluation systems, and new modality technologies, so please check our website for more information.
Inquiry
OpenInnovation@daiichisankyo.co.jpTAISHO PHARMACEUTICAL CO., LTD.
(Added on July 29, 2024)
TAIHO PHARMACEUTICAL CO., LTD.
Aiming to develop new treatments for refractory cancers.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Updated on December 1, 2025) (Listed on December 1, 2025)
Takeda's major areas of exploration (as of September 2025):
- Oncology: Solid tumors (non-small cell lung cancer, thoracic malignancies including small cell lung cancer, colorectal cancer, digestive malignancies including pancreatic cancer, etc.), hematopoietic tumors
- Neuroscience: neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, etc.), neuromuscular diseases (ALS, DM1, etc.)
- Gastrointestinal and inflammatory: Fibrostenotic Crohn's disease, severe hepatic fibrosis, atopic dermatitis, systemic sclerosis, etc.
Tanabe Pharma Corporation
(Updated on December 1, 2025) (Listed on December 1, 2025)
Tanabe Pharma wishes to partner with companies, universities and research institutions in the following areas and fields of drug discovery and research and development.
Target Areas and Fields
- Neurological Diseases
- Autoimmune Diseases
- Cancer
Inquiry
partnering-ml@ml.tanabe-pharma.com
CHUGAI PHARMACEUTICAL CO., LTD.
TEIJIN PHARMA Limited
(Updated July 29, 2024)
TEIJIN PHARMA Limited promotes the following open innovation activities.
- Drug targets, drug seeds and novel evaluation systems for neurodegenerative and autoimmune diseases
- New Modality Technology Applicable to Rare Diseases, etc.
- Drug delivery technology to specific tissues, such as crossing the blood-brain barrier
We welcome proposals at the basic research stage, regardless of the acquisition of drug seeds.
Inquiry
Kazuya Takenouchi, Biomedical Research Institutek.takenouchi@teijin.co.jp
N-row
NIPPON KAYAKU CO., LTD.
We are vigorously pursuing research and development of novel anti-cancer drugs using small molecule drug discovery and biotechnology and macromolecular synthesis technologies in collaboration with external research institutions.
If you have any proposals for joint research, please contact us through the "About Joint Research" link in the Inquiries section below.
NIPPON SHINYAKU Co., Ltd.
We welcome information on drug discovery seeds, drug targets, and technologies that can be used for drug discovery. For more information, please visit our R&D partnering website.
Inquiry
R&D Partnering Officezz_mail_partnering@po.nippon-shinyaku.co.jp
NIPPON BOEHRINGER INGELHEIM CO.
(Added on July 29, 2024)
For inquiries, please contact
BIAlliance.JP@boehringer-ingelheim.comH-row
Hisamitsu Pharmaceutical Co.
(Listed on June 30, 2025)
Hisamitsu Pharmaceutical specializes in Transdermal Drug Delivery System (TDDS) and has created many drugs based on TDDS technology.
We are currently exploring open innovation opportunities with external partners with different perspectives and ideas to accelerate the development of innovative drugs.
We also offer opportunities to use our joint experimental space and our own research equipment in our research institute (SAGA Global Research Center) located in Tosu City, Saga Prefecture.
PFIZER JAPAN INC.
Bristol-Myers Squibb K.K.
Bristol-Myers Squibb is focused on the discovery and development of innovative medicines in areas of high unmet medical need, including oncology, hematology, cardiology, immunology, and neurology.
We are actively seeking partnership opportunities with academic institutions, research organizations, and biotechnology companies around the world, including Japan, Korea, and Taiwan, for drug seeds, precision medicine, biomarkers, and data analysis from the early to late stages of development.
Inquiry
Open Innovation Secretariatbms-join@bms.com
M-row
MARUHO CO., LTD.
(Updated July 29, 2024)
Please refer to the following link.
For inquiries about Partnering Life Sciences
Meiji Seika Pharma Co., Ltd.
(Updated on January 31, 2025) (Updated on January 31, 2025)
We focus on immuno-inflammation (autoimmune and chronic inflammatory diseases), cancer (blood cancer and cancer in general), and infectious diseases (vaccines, antiviruses, and anti-AMR drugs), and conduct drug discovery using nucleic acid medicine technology, mainly macromolecules (antibodies, etc.) and mRNA. The company is promoting new drug development through open innovation by collaborating with academia and startups, and research results are being achieved through the organic fusion and collaboration of researchers both inside and outside the company.
Inquiry
R&D Strategy Departmentakira.suwa@meiji.com
MOCHIDA PHARMACEUTICAL CO., LTD.
(Updated July 29, 2024)
Mochida's drug discovery research is particularly focused on "nucleic acid medicine" to create innovative new drugs that address unmet medical needs. By maximizing the excellent properties of nucleic acid medicine, we aim to create original and unprecedented drugs.